Yardley, Denise A <br/><br/>
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.  [electronic resource] 

 -  Breast cancer research and treatment  Apr 2020 
 - 647-655 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-020-05563-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Bridged-Ring Compounds--administration & dosage<br/>Chemotherapy, Adjuvant--mortality<br/>Cohort Studies<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Furans--administration & dosage<br/>Humans<br/>Ketones--administration & dosage<br/>Middle Aged<br/>Neoadjuvant Therapy--mortality<br/>Non-Randomized Controlled Trials as Topic<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Survival Rate<br/>Taxoids--administration & dosage<br/>Trastuzumab--administration & dosage